Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study
Gaciong, Z.
Kardiologia Polska 64(5): 548
2006
ISSN/ISBN: 0022-9032 PMID: 16752345 Document Number: 602861
Document emailed within 1 workday
Related Documents
Kalantzi, K.I.; Ntalas, I.V.; Chantzichristos, V.G.; Tsoumani, M.E.; Adamopoulos, D.; Asimakopoulos, C.; Bourdakis, A.; Darmanis, P.; Dimitriadou, A.; Gkiokas, S.; Ipeirotis, K.; Kitikidou, K.; Klonaris, I.; Kostaki, A.; Logothetis, D.; Mainas, K.; Mais, T.; Maragiannis, A.; Martiadou, K.; Mavronasos, K.; Michelongonas, I.; Mitropoulos, D.; Papadimitriou, G.; Papadopoulos, A.; Papaioakeim, M.; Sofillas, K.; Stabola, S.; Stefanakis, E.; Stergiou, D.; Thoma, M.; Zenetos, A.; Zisekas, S.; Goudevenos, J.A.; 2019: Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial Current Vascular Pharmacology 17(6): 635-643Piamsomboon, C.; Laothavorn, P.; Chatlaong, B.; Saguanwong, S.; Nasawadi, C.; Tanprasert, P.; Leelaprute, M.; Intayakorn, U.; Amornsak, N. 2001: Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation: 1 and 6-month follow-up Journal of the Medical Association of Thailand 84(12): 1701-1707
Young, F.E.; Nightingale, S.L.; Temple, R.A. 1988: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction JAMA 259(21): 3158-3160
Lindbloom, E.J.; Eaton, L.J. 2002: Cost effectiveness of aspirin vs clopidogrel for secondary prevention of coronary heart disease Journal of Family Practice 51(9): 789
Szmidt, M.; Grzelewska-Rzymowska, I.; Rozniecki, J.; Grzegorczyk, J. 1991: Neutrophil chemotactic activity after administration of aspirin during aspirin tolerance in patients with asthma and aspirin hypersensitivity Pneumonologia i Alergologia Polska 59(1-2): 16-21
Yokoyama, T.; Yamashita, K.; Yamasaki, F.; Ueta, T.; Manabe, M.; Nishiyama, T. 2003: Aspirin reversal--an incremental administration of aspirin shortens the bleeding time prolonged by low-dose aspirin Masui. Japanese Journal of Anesthesiology 52(4): 399-401
Hiatt, W.R. 2008: Aspirin for prevention of cardiovascular events Bmj 337: A1806
Katz, L.B.; Shriver, D.A. 1989: Rioprostil heals pre-existing aspirin-induced gastric lesions in dogs during daily aspirin administration without altering the anti-inflammatory or analgesic efficacy of aspirin Journal of Pharmacology and Experimental Therapeutics 251(2): 774-781
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Mutter, J.; Grandy, R.; Hulkower, S.; Stigleman, S. 2018: Clinical Inquiries: What are the benefits and risks of daily low-dose aspirin for primary prevention of CV events? Journal of Family Practice 67(4): 247-248
1980: The aspirin myocardial infarction study: final results. The Aspirin Myocardial Infarction Study research group Circulation 62(6 Pt 2): V79-V84
Gulløv, A.L.; Koefoed, B.G.; Petersen, P.; Pedersen, T.S.; Andersen, E.D.; Godtfredsen, J.; Boysen, G. 1998: Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study Archives of Internal Medicine 158(14): 1513-1521
Bretagne, J.F.; Feuillu, A.; Gosselin, M.; Gastard, J. 1984: Aspirin and gastroduodenal toxicity. a double-blind endoscopic study of the effects of placebo, aspirin and lysine acetylsalicylate in healthy subjects Gastroenterologie Clinique et Biologique 8(1): 28-32
Stalnikowicz-Darvasi, R. 1995: Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis Journal of Clinical Gastroenterology 21(1): 13-16
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Chua, D.; Legal, M.; Shalansky, S.J. 2009: Clopidogrel plus aspirin in atrial fibrillation New England Journal of Medicine 361(13): 1312-1313; Author Reply 1314-1315
Fontana, P.; Berdagué, P.; Reny, J.L. 2006: Haemostasis. Aspirin and clopidogrel platelet resistances Revue Medicale Suisse 2(47): 25-29
Pignone, M.; Mulrow, C. 2002: Antiplatelet therapy and atherosclerotic events. Risks and patients' values need to be included in decision about aspirin for prevention of coronary heart disease Bmj 324(7342): 917
Gupta, S.; Gupta, M.M. 2008: Aspirin and clopidogrel resistance-a myth or reality: an update Indian Heart Journal 60(3): 245-253